Adult Obesity — Pharmacological Interventions

Publication Date: October 19, 2022

Key Points

Key Points

  • The prevalence of obesity in the United States has increased dramatically over the past few decades from 30.5% in 1999–2000 to 41.9% in 2019–2020.
  • In adults, obesity-related complications such as cardiovascular disease, stroke, type 2 diabetes mellitus (T2DM), nonalcoholic steatohepatitis, obstructive sleep apnea, osteoarthritis, and certain types of cancer (e.g., colorectal cancer) have also increased, contributing to high morbidity and mortality.
  • Lifestyle intervention(s) has limited effectiveness and durability for most individuals.
  • Pharmacological therapies with high efficacy in achieving weight loss have seen limited use, partly due to lack of familiarity and limited insurance coverage.
  • A small number of providers are responsible for >90% of the anti-obesity medication prescriptions.

Treatment

...reatmen...

...n adults with obesity or overweight with wei...


...adults with obesity or overweight with weight-rel...


...n adults with obesity or overweight with weigh...


...ts with obesity or overweight with weig...


5. In adults with obesity or overweight...


...adults with obesity or overweight with weigh...


...s with obesity or overweight with weigh...


8. In adults with obesity or overw...


...adults with body mass index (BMI) be...


...besity MedicationsHaving trouble viewing ta...


...rmacological Interventions for Adults...